SAB Biotherapeutics (SABS) Change in Interest Receivables (2024 - 2026)
SAB Biotherapeutics (SABS) reported Change in Interest Receivables of $608280.0 for Q1 2026, up 1912.03% on a YoY basis from $30232.2 in Q1 2025, and up 57.25% quarter-over-quarter from $386827.0 in Q4 2025.
SAB Biotherapeutics (SABS) Change in Interest Receivables (2024 - 2026) Analysis & Trends
SAB Biotherapeutics has reported Change in Interest Receivables for 3 years, with the latest figure at $608280.0 in Q1 2026.
- For the quarter ending Q1 2026, Change in Interest Receivables rose 1912.03% year-over-year to $608280.0; the trailing twelve-month figure through Mar 2026 stood at $1.5 million (up 992.47% YoY), and the FY2025 full-year result was $891826.0, up 1522.83% from the prior year.
- Change in Interest Receivables for Q1 2026 stood at $608280.0, up from $386827.0 in the prior quarter.
- The five-year high for Change in Interest Receivables was $608280.0 in Q1 2026, with the low at -$127877.0 in Q3 2024.
- Historically, Change in Interest Receivables has averaged $172784.6 across 3 years, with a median of $31692.0 in 2024.
- Annual changes were most pronounced in 2025 — Change in Interest Receivables plunged 167.48% — and 2026, when it soared 1912.03%.
- SAB Biotherapeutics' Change in Interest Receivables stood at -$42092.0 in 2024, then jumped by 1019.0% to $386827.0 in 2025, then surged by 57.25% to $608280.0 in 2026.
- The last three Change in Interest Receivables figures came in at $608280.0 (Q1 2026), $386827.0 (Q4 2025), and $559954.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Interest Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | SAB Biotherapeutics | 214.77 Mn | 214.77 Mn | - | 608,280.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 608,280.00 |
| Dec 31, 2025 | 386,827.00 |
| Sep 30, 2025 | 559,954.00 |
| Jun 30, 2025 | -21,386.00 |
| Mar 31, 2025 | -33,569.00 |
| Dec 31, 2024 | -42,092.00 |
| Sep 30, 2024 | -127,877.00 |
| Jun 30, 2024 | 31,692.00 |
| Mar 31, 2024 | 193,232.00 |